Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab in Female Genital Tract Melanoma
NCT04593485Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Oct 2020
- Primary completion
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in Melanoma of the female genital tract (FGTM), sponsored by Fudan University. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
Melanoma of the female genital tract (FGTM)
Beyond the preview
Go deeper on NCT04593485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04593485.